1. Home
  2. PHUN vs EQ Comparison

PHUN vs EQ Comparison

Compare PHUN & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Phunware Inc.

PHUN

Phunware Inc.

HOLD

Current Price

$1.89

Market Cap

55.9M

Sector

Technology

ML Signal

HOLD

EQ

Equillium Inc.

HOLD

Current Price

$1.11

Market Cap

57.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PHUN
EQ
Founded
2009
2017
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
55.9M
57.8M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
PHUN
EQ
Price
$1.89
$1.11
Analyst Decision
Buy
Hold
Analyst Count
2
1
Target Price
$7.25
$1.00
AVG Volume (30 Days)
152.4K
529.6K
Earning Date
11-06-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,357,000.00
$4,392,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$73.07
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.77
$0.27
52 Week High
$6.29
$2.35

Technical Indicators

Market Signals
Indicator
PHUN
EQ
Relative Strength Index (RSI) 37.88 51.32
Support Level $1.77 $0.84
Resistance Level $2.12 $1.26
Average True Range (ATR) 0.10 0.13
MACD -0.01 0.04
Stochastic Oscillator 27.38 46.66

Price Performance

Historical Comparison
PHUN
EQ

About PHUN Phunware Inc.

Phunware Inc is a software company. It is a cloud platform for mobile that provides companies with the products, solutions, and data and services necessary to engage, manage and monetize its mobile application audiences. It derives maximum revenue from United States. The company has two reportable segments: Software subscriptions and services; and Advertising. It derives maximum revenue from Software subscriptions and services.

About EQ Equillium Inc.

Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.

Share on Social Networks: